1. Corporate Social Responsibility as a Driver for Improved Sustainability

    Allain de Wilde, Corporate Social Responsibility Director and Loïc Allanos, Corporate Social Responsibility Manager for Servier Group, describe the how the industry can meet CSR standards.

  2. Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance

    When engineering and designing today’s OSD manufacturing facilities, the primary goal is to develop an operation that provides for the highest levels of product quality and operational efficiency, says Dave DiProspero, Associate/Director of Pharmaceutical Process Technology at CRB USA.

  3. Strengthening the Outsource Service Offering through Integration

    Controlling costs and increasing efficiencies are two fundamental drivers for outsourcing of pharmaceutical manufacturing, explains Luigi Trussardo, CEO of Olon Ricerca Bioscience.

  4. Achieving Controlled Nucleation During Aseptic Lyophilization

    Controlled nucleation is essential for obtaining high-quality lyophilized products with intra- and inter-batch consistency, says Robert Darrington, VP, Technical Marketing, SP Industries, Inc.

  5. Experience Meets Flexibility
    Terry Novak, Chief Operating Officer for Tedor Pharma discusses how to meet demands of an increasingly complex global OSD market
  6. State-of-the-Art Biologics Manufacturing in an Unexpected Location

    Vladas Algirdas Bumelis, Chief Executive Officer and Chairman of the Board for Biotechpharma comments on how the company, located in Lithuania is exporting biologic drug substances worldwide.

  7. WuXi STA First CDMO to Support the Approval of an Innovative Drug in China Through the "MAH" Pilot

    WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo (R).

  8. The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina

    The approval covers: Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG and 62.5 MG/25 MG, a generic version of GlaxoSmithKline's Malarone® (atovaquone and proguanil hydrochloride) Tablets.

  9. China Grants First Approval for PD-1/L1 Checkpoint Inhibitor
    The China Drug Administration approved Bristol-Myers Opdivo as a 2nd line treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
  10. Could a Bispecific Antibody Be A Functional Cure for AIDS?

    Hong Kong University researcher Chen Zhiwei reports successful results in mouse models.

  11. HPAPI’s and Two-Piece Liquid-Fill Capsules: The Perfect Match

    For oral solid dosage (OSD) drugs, formulating highly potent APIs as liquids in hard-shell capsules provides significant advantages over OSD forms, including soft-shell capsules, explains Tom Breshamer, Operations Manager for CapsCanada.

  12. WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients

    Jason Liu, Ph.D., MBA, SVP of WuXi AppTec and COO of Laboratory Testing Division and Francis L. Tse, Ph.D., VP of WuXi AppTec and CSO / Head of US Sites of the Laboratory Testing Division describe how WuXi AppTec’s Laboratory Testing Division (LTD) has expanded its global footprint.

  13. Successful Solid Dose Equipment Training

    Helping operators become technicians and building strong production teams requires training on machine set up, operation, cleaning, and maintenance, explains Mike Tousey, Technical Director/CEO of Techceuticals.

  14. Transforming A CDMO Using an Operational Excellence Approach
    Sébastien Mathieu, Industry Performance Deputy Director and Laurent Dray, Industry Performance Leader for Servier CDMO explain how to improve productivity and efficiency, reduce costs and environmental impacts and enhance quality assurance through operational excellence.
  15. Small Molecule Injectable Manufacturing: Challenges and Complexities

    Marga Viñes, Business Development Manager for Grifols, explains concentrated and diluted small molecule parenteral formu­lation options.

  16. Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

    Next-generation viral vector and gene therapy manufacturing facilities must be flexible, says Thomas Page, Ph.D., Vice President of Engineering and Asset Development for Fujifilm Diosynth Biotechnologies.

  17. Will Rapid Genome Sequencing Become A Standard Practice for Acutely Ill Infants?
    Rapid whole genome sequencing has the potential to save lives and prevent permanent brain and organ damage in infants.
  18. French Pharma Company Ipsen Moves US Headquarters from New Jersey to Boston

    Firm will join its manufacturing and R&D sites in the East Kendall area.

  19. StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform

    The financing was led by Hatteras Venture Partners. Co-investors include Takeda Ventures, Inc., UCB Ventures, and Alexandria Venture Investments, LLC. 

  20. BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

    CoA Therapeutics' lead compound will be entering the clinic in 2019 with a planned initial focus on pantothenate kinase-associated neurodegeneration, or PKAN.

View All

Road To BIO: Coming Soon To Your Screen Q4 2018
The Road to BIO in Review
The Road To BIO: Day 12 California
The Road To BIO: Day 11 Arizona /// California
The Road To BIO: Day 10 Texas /// Arizona
The Road To BIO: Day 9 Texas
The Road To BIO: Day 8 Texas
The Road To BIO: Day 7 Mississippi /// Texas
The Road To BIO: Day 6 Georgia /// Mississippi
The Road To BIO: Day 5 South Carolina /// Georgia
The Road To BIO: Day 4 Tennessee /// South Carolina
The Road To BIO: Day 3 Pennsylvania /// Tennessee
The Road To BIO: Day 2 New York /// Pennsylvania
For Your Listening Pleasure
The full story of this epic journey can be experienced as an audiobook. Listen to the story behind the story – the characters, the challenges, and all 12 days of the Road To BIO.
Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.
Drug Discovery

Could a Bispecific Antibody Be A Functional Cure for AIDS?

Jun 19, 2018 1:14:03 PM PAO-M06-18-NI-015
Drug Development

China Grants First Approval for PD-1/L1 Checkpoint Inhibitor

Jun 19, 2018 1:11:20 PM PAO-M06-18-NI-014

French Pharma Company Ipsen Moves US Headquarters from New Jersey to Boston

Jun 15, 2018 1:00:09 PM PAO-M06-18-NI-013
Cell and Gene Therapy

Will Rapid Genome Sequencing Become A Standard Practice for Acutely Ill Infants?

Jun 15, 2018 12:53:46 PM PAO-M06-18-NI-012
Oral Solid Dose

HPAPI’s and Two-Piece Liquid-Fill Capsules: The Perfect Match

Jun 14, 2018 3:42:01 PM PAO-06-18-CL-001

Hormone Therapy Appears to Be the Best Bet for Treating Early Breast Cancer

Jun 14, 2018 1:00:03 PM PAO-M06-18-NI-011

Pfizer Expands Investment in Biotech through Pfizer Ventures

Jun 14, 2018 12:55:15 PM PAO-M06-18-NI-010
Combination Treatment

FDA Approves Venclexta/Rituxan Combination Treatment for Leukemia

Jun 12, 2018 2:35:44 PM PAO-M06-18-NI-009

Preliminary Data Suggests DENKI Pain Blockers Don’t Have Abuse Potential

Jun 12, 2018 2:29:55 PM PAO-M06-18-NI-008

Another mAb Biosimilar on the Horizon in Europe

Jun 5, 2018 2:14:21 PM PAO-M06-18-NI-006

Funding Round Will Boost Efforts to Develop Antibiotic for Alzheimer’s Disease

Jun 5, 2018 2:11:05 PM PAO-M06-18-NI-005

Nice Insight Overview

Changes in the  Biopharma Industry: from Minor to Major Evolution
New technologies such as gene editing are leading to the development of even more advanced, targeted medicines.

The Next-Generation Player

Addressing Development Challenges for Complex Biologic Drug Candidates
At Lonza, we are constantly looking to reduce the development timeline, giving our customers more control over their projects.

Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing Lonza Pharma & Biotech

M+A Column

Inside Mergers & Acquisitions
Kevin Bottomley Partner, Results Healthcare
Deals in the pharmaceutical industry are an important mechanism of acquiring innovation, business and efficiency.

Nice Insight Overview

Doping: Famous Cases, Substances and Values in Sports

Marc Technow, Nice Insight